MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Earlier this month, Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory ...

Shares of Moderna dropped more than 20% intraday to $33.44, more than erasing gains last week after the first bird-flu death ...

Moderna MRNA5.37%increase; green up pointing triangle secured a $590 million package from the U.S. Health and Human Services Department to accelerate the development of its bird influenza vaccine ...